top of page
SBC Logo 200 px x 200 px.png
Accessibility Tools

Upcoming
events

Circulating Tumor DNA (ctDNA) in Breast Cancer: Pioneering Insights into Precision Medicine

Writer's picture: Surviving Breast CancerSurviving Breast Cancer

In the ever-evolving landscape of cancer research, the emergence of circulating tumor DNA (ctDNA) has revolutionized the field of oncology, offering a promising avenue for early detection, monitoring, and personalized treatment strategies in breast cancer.

Understanding ctDNA: What is it and How Does it Relate to Breast Cancer?


ctDNA, often referred to as "liquid biopsy," consists of small fragments of DNA released into the bloodstream by tumor cells as they undergo cell death or turnover. These minute traces of genetic material carry valuable information about the genomic alterations specific to the tumor, reflecting its heterogeneity.


In the context of breast cancer, ctDNA analysis provides an opportunity to comprehensively study the tumor's genetic profile without the need for invasive procedures like tissue biopsies. This non-invasive approach holds tremendous potential for monitoring disease progression, detecting minimal residual disease (MRD), and tracking treatment response, ushering in an era of precision medicine tailored to individual patients.


The Role of ctDNA in Breast Cancer Detection and Monitoring

Early detection remains pivotal in improving breast cancer outcomes. ctDNA analysis presents a promising tool for detecting cancer at earlier stages, even before clinical symptoms manifest. By identifying specific genetic mutations or alterations characteristic of breast cancer, ctDNA assays enable the identification of minimal residual disease post-surgery or after completing treatment, aiding in assessing the risk of disease recurrence.


Moreover, ctDNA monitoring allows for real-time tracking of treatment response and disease progression. Changes in ctDNA levels or alterations in the genetic profile can provide vital insights into the tumor's behavior, allowing oncologists to adapt treatment plans promptly for optimal therapeutic outcomes.


breast cancer support programs and events

Harnessing ctDNA for Personalized Treatment Strategies